Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In his letter, the author reports that regular corticosteroid and corticotropin therapy was associated with hair growth and the return of pigment in patients with alopecia totalis.

This study found that lower dietary protein with supplemented methionine allowed blue foxes to grow normally and produce high-quality pelts while reducing feed costs and environmental phosphorus and nitrogen loads.

This study reports that intramuscular compound betamethasone may offer rapid, short-term reduction in hair shedding for patients with telogen effluvium, particularly within a week, but often requires repeated treatments; only mild side effects were observed.

In this study, photobiomodulation therapy applied twice weekly for 12 weeks significantly improved hair regrowth and quality of life in alopecia areata patients, with no noted side effects.

Taking dutasteride every other day works as well as daily and better preserves sexual function.

Using Selenium Disulfide shampoo weekly helps prevent scalp dermatitis flare-ups.

In this study, baricitinib for severe alopecia areata showed sustained efficacy over 104 weeks, with most Week-52 responders maintaining significant hair regrowth and some mixed responders improving further with long-term treatment.

This literature watch compiles recent studies on photobiomodulation therapy across various applications, offering no new empirical findings.

This study found that azathioprine pulse therapy and betamethasone both effectively managed alopecia areata with similar hair regrowth results, though betamethasone had significantly more side effects, suggesting azathioprine as a preferable alternative to corticosteroids.

This study reported that applying Serum WS Biotin, a water-soluble form of D-Biotin, daily for 3 months significantly reduced hair shedding and increased hair strength in volunteers with moderate to excessive hair shedding, while showing good skin compatibility.

Treating psoriasis with UVB light three times a week is faster than twice a week, and certain medications and lifestyle factors affect psoriasis treatment outcomes.

This study found that adults with atopic dermatitis who were treated with baricitinib at doses of 2mg or 4mg experienced significant improvements in work productivity, potentially leading to substantial indirect cost savings for employers over 16 weeks.

This study found that an intermittent low-dose regimen of finasteride (2.5 mg every 3 days) effectively reduced hirsutism scores in women with idiopathic hirsutism or polycystic ovary syndrome, with fewer side effects than continuous daily administration.

The researchers reported that baricitinib treatment for at least 52 weeks reduced severe alopecia areata severity and improved psychological well-being and quality of life in study participants.

In this case report, two women with chronic alopecia areata and acute alopecia universalis experienced sustained and near-complete hair regrowth after over a year of treatment with oral ruxolitinib, without significant side effects.

This review discusses the safety and potential adverse events of microneedling as both a medical and consumer product, noting the need for further understanding; no new clinical results are presented.

In this study, a combination of terbinafine and mitotane was used to treat a dog with pituitary-dependent hyperadrenocorticism and dermatophytosis, showing regrowth of hair and negative fungal cultures without detectable adverse effects.

This study highlights the significant risk of vascular embolism associated with hyaluronic acid filler injections, emphasizing concerns about potential irreversible damage when fillers are injected in "unexplored" facial areas due to complex and variable facial anatomy.

This study reviews potential immune targets within hair follicles in alopecia areata, suggesting they may be associated with keratinocytes or melanocytes, and notes possible induction triggers like viruses and infections.

This case report suggests that topical diphenylcyclopropenone (DPCP) may be beneficial for treating both alopecia areata and verruca vulgaris, although it is not typically a first-line therapy.